Obalon Therapeutics Inc (OBLN) Stock Price, Forecast & Analysis
USA - NASDAQ:OBLN -
OBLN Key Statistics, Chart & Performance
The current stock price of OBLN is 3.05 null. In the past month the price increased by 29.24%. In the past year, price increased by 296.1%.
OBLN Latest News, Press Relases and Analysis
OBLN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.32 | 219.92B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.04 | 200.75B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.91 | 148.20B | ||
| SYK | STRYKER CORP | 27.03 | 136.11B | ||
| IDXX | IDEXX LABORATORIES INC | 56.18 | 56.68B | ||
| BDX | BECTON DICKINSON AND CO | 12.33 | 50.97B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.45 | 48.96B | ||
| RMD | RESMED INC | 25.4 | 36.70B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.92 | 33.35B | ||
| PODD | INSULET CORP | 75.61 | 22.51B | ||
| DXCM | DEXCOM INC | 29.57 | 21.57B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Related stock screener links
About OBLN
Company Profile
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The company is headquartered in Carlsbad, California and currently employs 2 full-time employees. The company went IPO on 2016-10-06. The firm's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The firm has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
Company Info
Obalon Therapeutics Inc
5421 Avenida Encinas Ste F
Carlsbad CALIFORNIA 92008 US
CEO: Andrew Rasdal
Employees: 2.0
Phone: 18584802400.0
Obalon Therapeutics Inc / OBLN FAQ
What does OBLN do?
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The company is headquartered in Carlsbad, California and currently employs 2 full-time employees. The company went IPO on 2016-10-06. The firm's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The firm has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
What is the current price of OBLN stock?
The current stock price of OBLN is 3.05 null. The price decreased by -5.86% in the last trading session.
What is the dividend status of Obalon Therapeutics Inc?
OBLN does not pay a dividend.
How is the ChartMill rating for Obalon Therapeutics Inc?
OBLN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of Obalon Therapeutics Inc (OBLN)?
Obalon Therapeutics Inc (OBLN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.17).
Can you provide the market cap for Obalon Therapeutics Inc?
Obalon Therapeutics Inc (OBLN) has a market capitalization of 30.57M null. This makes OBLN a Nano Cap stock.
Can you provide the upcoming earnings date for Obalon Therapeutics Inc?
Obalon Therapeutics Inc (OBLN) will report earnings on 2022-03-11, after the market close.
OBLN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to OBLN. When comparing the yearly performance of all stocks, OBLN is one of the better performing stocks in the market, outperforming 95.43% of all stocks.
OBLN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OBLN. Both the profitability and financial health of OBLN have multiple concerns.
OBLN Financial Highlights
Over the last trailing twelve months OBLN reported a non-GAAP Earnings per Share(EPS) of -3.17. The EPS increased by 76.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1391.09% | ||
| ROA | -64.81% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
OBLN Forecast & Estimates
0 analysts have analysed OBLN and the average price target is 18.82 null. This implies a price increase of 517.02% is expected in the next year compared to the current price of 3.05.
For the next year, analysts expect an EPS growth of 43.12% and a revenue growth 953.33% for OBLN